Founded- 2001, 18+ years.
Headquarters- Mumbai, Maharashtra.
Area served- Worldwide.
Key people- Mr Glenn Saldanha, Yasir Rawjee, V. S. Mani.
Products- APIs (Active Pharmaceutical Ingredients).
Revenue- 18,859.76 Cr
Number of employees- 1400 plus.
Glenmark Life Science is India’s leading pharmaceutical company, it was founded in 2001, and its headquarters is situated in Mumbai, India. The company spun off into Glenmark Pharmaceutical to establish its APIs (Active Pharmaceutical Ingredients) business. Glenmark Life Science making high-quality drugs, and APIs, established strong relationships with global generic Pharmaceutical companies.
Glenmark Life Science was started independently from Glenmark Pharmaceutical in 2001, it’s mainly focused on the APIs manufacturing business. Also, the company develops, manufactures, and supplies high-quality drugs, and APIs to the global market.
2001- The company separated from Glenmark Pharmaceutical.
2002- Glenmark Life Science established its first manufacturing plant at Kurkumbh MIDC, Pune, Maharashtra.
2003- The company’s first product was registered with the US FDA (Food & Drug Administration) and Also acquired the Glaxo SmithKline (GSK) API manufacturing plant in Ankleshwar, Gujrat.
2004- Glenmark Life Science commenced manufacturing facility at Mohol, Maharashtra.
2012- Its Ankleshwar manufacturing facility was inspected by the Japanese regulatory agencies PMDA (Pharmaceutical & Medical Device Agency) and AFSSAPS.
2013- Glenmark Life Science also commenced the third manufacturing plant at Dahej, Gujrat, and In the same year, the Ankleshwar plant was inspected by COFEPRIS.
2015- Dahej plant inspected by US FDA.
2016- Dahej plant was also inspected by PMDA Japan
2018- The company Dahej manufacturing plant was inspected by EDQM, ANSM, US FDA, and the Mohol plant was inspected by the US FDA.
2019- The APIs business was separated from Glenmark Pharmaceutical. The Ankleshwar manufacturing plant was inspected by US FDA, Health Canada and PMDA, Japan agency.
2021- Glenmark Life Science has achieved 403 cumulative drug master files across multiple markets globally.
Products and services
Glenmark Life Science’s products portfolio consists of 120 APIs across various therapeutics segments such as Diabetes, central nervous system (CNS), Cardiovascular disease (CVS), Gastrointestinal Health, Oncology, Pain Management, and Anti-infective. The company Partner with the world’s 16 of the top 20 generic pharmaceutical companies and serve customers in different geographies including Europe, Japan, North America, Latin America, India, and ROW. Glenmark Life Science has 18-plus years of experience in APIs development and manufacturing. its plant can handle production scale from grams to multi tons product manufacturing.
Manufacturing and R&D Facilities
Glenmark Life Science has reliable, high-quality, and advanced manufacturing facilities at four locations like Kurkumbh, Dahej, Mohol, and Ankleshwar in India. It’s all manufacturing facilities’ annual production capacity of over 550 MT. The company Ankleshwar and Dahej plant was inspected by the US FDA, PMDA, and KFDA regulator agencies.
Glenmark Life also owned three in-house research and development centers. These centres have chemistry capabilities including Polymorphism screening and Optimization, Cryogenic reactions, High-pressure reactions, High-temperature reactions, Enzymatic transformation, and particle size distribution studies.
The company plans to raise Rs 1513 Cr from the public offering. It comprises fresh issue shares worth Rs 1060 Cr and an offer for sale of Rs 453 Cr. The IPO open date is 27 July 2021 and the close date is July 29, 2021. The shares issue or listing date is August 6, 2021, and the allotted shares will be credited to your Demat account by Aug 5, 2021. The Grey Market Premium (GMP) for Glenmark Life Sciences shares at Rs 140 on July 28.
This stands against its price band of Rs 695 to Rs 720 per share. The shares traded at the unlisted market at Rs 835 to Rs 860 per share over the initial price issue. The share is listed on the BSE and NSE platforms for a 4 % premium over the issue price of Rs 720 per share. It was trading at Rs 760 with a 5.6 percent premium on the NSE and 756.05 with a 5.01 percent premium on the BSE. The IPO was oversubscribed 44.17 times on 27 July 2021 but it disappointed all investors.
- The company has strong fundamentals and a good track record of strong financial performance.
- It’s a leading manufacturer of APIs in India and owns 4 manufacturing facilities.
- The company exports products to global markets like Europe, Latin America, North America, Japan, and the rest of the world.
- Glenmark Life Science maintains strong relationships with global generic Pharmaceutical companies.
Palle V R Acharyulu
Vice President of (R&D)
Vice President Human Resources
Area Served- Worldwide.
Parent- Glenmark Pharmaceutical.